Table 1.
Clinicopathologic characteristics of the melanoma cohort treated with immune checkpoint inhibitors and non-immunotherapy-treated melanoma cohort
| Yale ITx melanoma cohort (YTMA376 – n = 60) |
Yale non-immunotherapy-treated cohort (YTMA76 – n = 131) |
|
|---|---|---|
| Characteristics | n (%) | n (%) |
| Sex | ||
| Female | 26 (43) | 73 (56) |
| Male | 34 (57) | 50 (38) |
| Unknown | 8 (6) | |
| Age | ||
| <60 | 24 (40) | |
| ≥60 | 36 (60) | |
| Mean±SD (range) | 61 ± 16.8 (6–86) | |
| Stage | ||
| I | 10 (17) | 63 (48) |
| II | 11 (18) | 38 (29) |
| III | 22 (37) | 18 (14) |
| IV | 12 (20) | |
| Unknown | 4 (8) | 12 (9) |
| RECIST groups | ||
| CR/PR | 26 (43) | |
| SD | 18 (30) | |
| PD | 16 (27) | |
| Treatment | ||
| Nivolumab | 11 (18) | |
| Pembrolizumab | 24 (40) | |
| Ipilimumab plus Nivolumab |
25 (42) | |
| Prior immune checkpoint blockade | ||
| Yes | 16 (27) | |
| No | 44 (73) | |
| Mutation status | ||
| BRAF | 19 (32) | |
| NRAS | 8 (13) | |
| CKIT | 1 (3) | |
| None detected | 31 (52) | |
|
Location of primary tumor |
||
| Extremity | 57 (44) | |
| Trunk | 66 (50) | |
| Unknown | 8 (6) | |
|
Follow-up in months DSOS – Median (IQT) |
76.9 (64) |